The negative prognostic impact of the fms‐like tyrosine kinase receptor‐3 internal tandem duplication mutation (FLT3/ITD) on AML outcome and its physiologic effect of constitutive signalling through a receptor tyrosine kinase make it a highly desirable drug target. This evidence concerns the gene FLT3 and acute myeloid leukemia.